Stem Cell Research Now and in the Future
November 2009. November 2009. “Stem cells provide novel opportunities that didn't previously exist” says Patrick Vallance, President Pharmaceuticals, R&D of GlaxoSmithKline in the interview with B2Bioworld. He describes his company’s approach. What is the role of cancer stem cells? What about novel drugs like lapatinib or trastuzumab? Which collaborations are desirable? The interview includes stem cell issues yet unattended by pharma.
Includes Tumour Therapy Basic Approaches; detailed chart: GSK Partnering Capabilities
Reading time: 5 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Novartis and Stem Cells
Mark Fishman, President Novartis Institutescomments on the company’s strategy and technology acquisitions in the field
Personalised Medicine: Let’s be clear what it means
Jonathan K.C. Knowles, at the time Head of Group Research Roche about his motivations, work in Roche, and competitors
Sanofi: Triggering Regenerative Functions
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis
Strategic ambiguities with "stem cells"
Bernd Kirschbaum,Global Discovery and Early Development Merck Serono on strategic ambiguities in technology development